Evidence map›Paper›PMID 30303964›Full record

ArticlePloS one2018

The modular network structure of the mutational landscape of Acute Myeloid Leukemia.

Mariam Ibáñez, José Carbonell-Caballero, Esperanza Such, Luz García-Alonso, Alessandro Liquori, María López-Pavía, Marta Llop, Carmen Alonso, Eva Barragán, Inés Gómez-Seguí and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Mariam IbáñezHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.ORCID 0000-0002-7486-4659
José Carbonell-CaballeroProCURE, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
Esperanza SuchHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Luz García-AlonsoEuropean Molecular Biology Laboratory-European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
Alessandro LiquoriHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
María López-PavíaHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Marta LlopCentro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.
Carmen AlonsoHematology Service, Hospital Arnau de Villanoba, Valencia, Spain.
Eva BarragánCentro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.
Inés Gómez-SeguíHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Alexander NeefHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
David HervásBiostatistics Unit, IIS La Fe Valencia, Spain.
Pau MontesinosHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Guillermo SanzHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Miguel Angel SanzHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Joaquín DopazoFunctional Genomics Node, Spanish National Institute of Bioinformatics at CIPF, Valencia, Spain.ORCID 0000-0003-3318-120X
José CerveraHematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Hospital Universitari i Politècnic La Fe · ESEuropean Bioinformatics Institute · GBFundación Progreso y Salud · ESHospital Arnau de Vilanova · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Investigación Sanitaria La Fe · ESUniversidad Cardenal Herrera CEU · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is associated with the sequential accumulation of acquired genetic alterations. Although at diagnosis cytogenetic alterations are frequent in AML, roughly 50% of patients present an apparently normal karyotype (NK), leading to a highly heterogeneous prognosis. Due to this significant heterogeneity, it has been suggested that different molecular mechanisms may trigger the disease with diverse prognostic implications. We performed whole-exome sequencing (WES) of tumor-normal matched samples of de novo AML-NK patients lacking mutations in NPM1, CEBPA or FLT3-ITD to identify new gene mutations with potential prognostic and therapeutic relevance to patients with AML. Novel candidate-genes, together with others previously described, were targeted resequenced in an independent cohort of 100 de novo AML patients classified in the cytogenetic intermediate-risk (IR) category. A mean of 4.89 mutations per sample were detected in 73 genes, 35 of which were mutated in more than one patient. After a network enrichment analysis, we defined a single in silico model and established a set of seed-genes that may trigger leukemogenesis in patients with normal karyotype. The high heterogeneity of gene mutations observed in AML patients suggested that a specific alteration could not be as essential as the interaction of deregulated pathways.

Indexed as

Exome SequencingAdultAgedCytodiagnosisFemaleGene Regulatory NetworksGenetic Association StudiesGenetic HeterogeneityHumansKaryotypeLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNeoplasm ProteinsNucleophosminNeoplasm ProteinsNPM1 protein, humanNucleophosmin

Identifiers

PMID30303964
PMCPMC6179200
OpenAlexW2896973056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.